A point-of-care solution, regardless of the situation.

Because ClotChip® technology is an assay, it is uniquely capable of serving urgent needs for a number of clinical markets.

ClotChip® measurements have been used in the study of whole-blood coagulation related to congenital disorders, anticoagulant treatments, trauma patients in the civilian and military sectors, and in studies of patients prior to surgery.

Congenital Disorders

Congenital hemophilia affects up to ~33,000 people in the U.S. ( and more than 1,000,000 people globally (Ann Int Med 2019: 171(8)).

With hemophilia, every bleed is important yet there is currently no known point-of-care diagnostic test to inform clinician care.

ClotChip® is poised to be the point-of-care diagnostic device to inform clinicians in treating those affected by hemophilia.

Oral Anticoagulant Therapy Monitoring

Therapeutic use of anticoagulants is common in prevention and treatment of potentially deadly blood clots and the use of Direct Oral Anticoagulants (DOACs) has gained favor in replacing use of traditional blood thinners such as heparins and vitamin K antagonists (Warfarin) (Crit Care. 2016 20(1):273).

DOAC therapeutics work by blocking either thrombin directly, or factor Xa within the coagulation cascade. While these drugs are beneficial overall, there are numerous reports of life threatening spontaneous bleeding in patients undergoing treatment with these therapeutics.

ClotChip® is positioned to be the point-of-care diagnostic device to inform clinicians in monitoring and informing treatment with DOAC therapies. Specifically, XaTek® is pursuing the use case for ClotChip® as a peri-operative screening tool for patients on DOAC therapy immediately prior to an invasive procedure.

See press release on FDA’s Breakthrough Device Designation.


Uncontrolled bleeding from traumatic injuries in civilian and military settings can often lead to organ failure and, eventually, death. Currently there is no no standardized method for field assessment of a patient’s coagulation state in trauma-induced coagulopathy (Shock. 2014 41 Suppl 1(0 1):35-8).

ClotChip® been studied at the point-of-care in trauma centers and in field use (e.g., ambulances and/or helicopters), to inform care and use of precious blood products.

The ruggedization of ClotChip® for field use was funded by the Department of Defense’s Combat Readiness Medical Research Program, in cooperation with the U.S. Navy.

See press release on XaTek’s cooperative work with the U.S. Navy.

Pre-Surgical Applications

Coming soon

Technology questions?